Alpha 2.0
Login Register
» Articles » PMID: 18477046

Combination of the Anti-CD30-auristatin-E Antibody-drug Conjugate (SGN-35) with Chemotherapy Improves Antitumour Activity in Hodgkin Lymphoma

Overview
Journal Br J Haematol
Specialty Hematology
Date 2008 May 15
PMID 18477046
Citations 39
Authors
Ezogelin Oflazoglu
Kim M Kissler
Eric L Sievers
Iqbal S Grewal
Hans-Peter Gerber
Affiliations
Soon will be listed here.
Abstract

The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-CD30 monoclonal antibody cAC10. This ADC potently interferes with the growth of CD30-positive haematological tumours, including Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma. This study found improved antitumour activity in a preclinical model of HL when SGN-35 was combined with chemotherapeutic regimens such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or gemcitabine. Improved efficacy was also observed in high tumour burden models, indicating that combining ADCs with chemotherapeutic agents may be advantageous for the treatment of patients with relapsed or refractory HL.

Citing Articles

Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism.

Jiang Y, Dong S, Wang Y Cancers (Basel). 2025; 17(3).

PMID: 39941862 PMC: 11815818. DOI: 10.3390/cancers17030496.

Impact of Various Forced Oxidative Stress Factors in Rapid Degradation of mAb: Trastuzumab as a Case Study.

Sreenivasan S, Rathore A Pharm Res. 2025; 42(2):335-351.

PMID: 39849217 DOI: 10.1007/s11095-025-03816-4.

The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.

Sasso J, Tenchov R, Bird R, Iyer K, Ralhan K, Rodriguez Y Bioconjug Chem. 2023; 34(11):1951-2000.

PMID: 37821099 PMC: 10655051. DOI: 10.1021/acs.bioconjchem.3c00374.

Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review.

Radhakrishnan V, Bajaj R, Raina V, Kumar J, Bhave S, Sukumaran Nair R Front Oncol. 2022; 11:796270.

PMID: 35127505 PMC: 8814627. DOI: 10.3389/fonc.2021.796270.

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.

Tong J, Harris P, Brimble M, Kavianinia I Molecules. 2021; 26(19).

PMID: 34641391 PMC: 8510272. DOI: 10.3390/molecules26195847.

References
1.
Kuppers R, Rajewsky K . The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol. 1998; 16:471-93. DOI: 10.1146/annurev.immunol.16.1.471. View
2.
Francisco J, Cerveny C, Meyer D, Mixan B, Klussman K, Chace D . cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003; 102(4):1458-65. DOI: 10.1182/blood-2003-01-0039. View
3.
Duggan D, Petroni G, Johnson J, Glick J, Fisher R, Connors J . Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003; 21(4):607-14. DOI: 10.1200/JCO.2003.12.086. View
4.
Zupi G, Scarsella M, DAngelo C, Biroccio A, Paoletti G, Lopez M . Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther. 2005; 4(8):866-71. DOI: 10.4161/cbt.4.8.1895. View
5.
Younes A, Kadin M . Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol. 2003; 21(18):3526-34. DOI: 10.1200/JCO.2003.09.037. View